多西他赛联合希罗达治疗转移性乳腺癌的临床观察

Clinical observation of Docetaxel and Xeloda Combination in treatment of 38 cases with metastatic breast cancer

目的:观察多西他赛联合希罗达治疗转移性乳腺癌的临床近期疗效及不良反应。方法:将38例转移性乳腺癌患者采用多西他赛联合希罗达方案治疗,多西他赛75 mg/m2静脉滴注,第1天;希罗达2 500 mg/(m2.d),餐后口服,每日2次,连续服用2周,每3周为1个周期,4个周期结束,评价疗效,记录不良反应。结果:38例患者均可取得较好的临床近期疗效,不良反应主要为胃肠道反应、骨髓抑制和手足综合征,均可耐受,无治疗相关死亡患者。结论:多西他赛联合希罗达治疗转移性乳腺癌有较好的近期疗效,不良反应可以耐受。

Objective：To observe the efficacy and toxicity of Docetaxel and Xeloda combination regimen in patients with metastatic breast cancer.Methods：Thirty-eight patients with metastatic breast cancer were all treated with Docetaxel and Xeloda combination regimen.Docetaxel 75 mg/m2 ivgtt,day1;Xeloda 2 500 mg/（m2·d） after 30 min of meal,twice daily,two weeks,repeated every 3 weeks as 1 cycle.Efficacy and toxicity were recorded in 4 cycles.Results：Thirty-eight patients who obtained better curative effect were evaluated.The main toxicities were gastrointestinal,myelosuppression toxicity and hand-foot syndrome,and were tolerable.There was no death associated with treatment.Conclusion：Docetaxel and Xeloda combination regimen is effective for metastatic breast cancer and well-tolerated.